Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 16Observational 1

Sponsor

Cancer Type

Genitourinary 18Gastrointestinal 4Sarcoma 3Tumor-Agnostic 1NET 1Lymphoid 1Endocrine 1

Conditions

Neoplasms 1Carcinoma 1

Interventions

Surveys and Questionnaires 48Blood Specimen Collection 23Interviews as Topic 14Data Collection 11Radiotherapy 6Magnetic Resonance Spectroscopy 6Hematologic Tests 6Specimen Handling 5Restraint, Physical 5Palliative Care 4Observation 4Mental Status and Dementia Tests 4Watchful Waiting 3Registries 3Quality of Life 3Phlebotomy 3Neoadjuvant Therapy 3Magnetic Resonance Imaging 3Lapatinib 3Immunotherapy 3Immune Checkpoint Inhibitors 3Health Records, Personal 3Focus Groups 3Drug Therapy 3Bevacizumab 3Absorptiometry, Photon 3veliparib 2talazoparib 2rucaparib 2pamiparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Sunitinib × Tumor-Agnostic × Clear all
NCT04033991 2023-04-06

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Pfizer

Completed
684 enrolled 20 charts
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡